齐拉西酮对精神分裂症患者执行功能障碍的影响
详细信息 查看官网全文
- 论文作者：杨淼 ; 穆晞园
- 年：2014
- 作者机构：金华市第二医院;
- 论文关键词：齐拉西酮 ; 氯丙嗪 ; 精神分裂症 ; 执行功能
- 会议召开时间：2014-11-20
- 会议录名称：2014浙江省医学会精神病学分会学术年会、浙江省医师协会精神科医师分会第七届年会论文汇编
- 语种：中文
- 分类号：R749.3
- 学会代码：ZJKX
- 会议名称：2014浙江省医学会精神病学分会学术年会、浙江省医师协会精神科医师分会第七届年会
- 会议地点：中国浙江湖州
- 主办单位：浙江省医学会精神病学分会（The Society of Psychiatry ; ZJMA）、浙江省医师协会精神科医师分会
- 学会名称：浙江省科学技术协会
- 页数：2
- 文件大小：141k
- 原文格式：O
- 会议级别：地方
摘要
目的:探讨齐拉西酮对精神分裂症患者执行功能障碍的长期疗效。方法:对32例服用齐拉西酮维持治疗与29例服用氯丙嗪维持治疗的精神分裂症患者进行1年随访,采用威斯康星卡片分类测验(WCST)评估执行功能。结果:维持治疗1年末齐拉西酮组和氯丙嗪组的WCST测验中的总测验次数、持续错误数非持续错误数均显著下降(p<0.05或p<0.01),但齐拉西酮组的总测验次数、持续错误数、随机错误数减分率均显著高于氯丙嗪组(p均<0.01)。结论:齐拉西酮长期维持治疗能显著改善精神分裂症患者的执行功能。
引文
[1]刘哲宁,赵靖平,谭伟象等.以阴、阳性症状为主的精神分裂症病人威斯康星卡片分类测验的比较研究[J].中华精神科杂志,1998,31(2):100-103.
[2]DANIEL D G,ZIMBROFF D L,POTKIN S G,et al.Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder:a 6-week placebocontrolled trail[J].Neuropsychopharmacology,1999,20(5):491-505.
[3]ADDINGTON D E,PANTELIS C.DINEEN M,et al.Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia and schizoaffective disorder:an 8-week,double-blind,multicenter trail[J].J Clin Psyschiatry,2004,65(12):1624-1633
[4]Daban C,Amado I,Bourdel MC,et al.Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia[J]J Psychiatr Res,2005,39:391-398.
[5]HARVEY P D,BOWIE C R,LOEBEL A,et al.Neuropsychological normalization with long-term atypical antipsychotic treatment:results of six-month randomized.J Neuropsychiatry Clin neurosci,2006,18(1):54-63.
[6]Tonmoy S.Cognitive effects of conventional and atypicalantipsychotics in schizophrenia[TJ.Br J Psychiatry,1999,174(Suppl38):44-45.
[7]Weiser M,Shneider-Beer M.Improment in cognition associated with novel antipsychotic drugs:a direct drug effct or reduction of EPS[J].Schizophr Res,2000,46:81-89.
[8]SCHMIDT A W,LEBEL L A,HOWARD H R J R.et al.Ziprasidone:a novel anti psychotic agent with aunique human receptor binding profile[J].Eur J Pharmacol,2001,425(3):197.
[2]DANIEL D G,ZIMBROFF D L,POTKIN S G,et al.Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder:a 6-week placebocontrolled trail[J].Neuropsychopharmacology,1999,20(5):491-505.
[3]ADDINGTON D E,PANTELIS C.DINEEN M,et al.Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia and schizoaffective disorder:an 8-week,double-blind,multicenter trail[J].J Clin Psyschiatry,2004,65(12):1624-1633
[4]Daban C,Amado I,Bourdel MC,et al.Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia[J]J Psychiatr Res,2005,39:391-398.
[5]HARVEY P D,BOWIE C R,LOEBEL A,et al.Neuropsychological normalization with long-term atypical antipsychotic treatment:results of six-month randomized.J Neuropsychiatry Clin neurosci,2006,18(1):54-63.
[6]Tonmoy S.Cognitive effects of conventional and atypicalantipsychotics in schizophrenia[TJ.Br J Psychiatry,1999,174(Suppl38):44-45.
[7]Weiser M,Shneider-Beer M.Improment in cognition associated with novel antipsychotic drugs:a direct drug effct or reduction of EPS[J].Schizophr Res,2000,46:81-89.
[8]SCHMIDT A W,LEBEL L A,HOWARD H R J R.et al.Ziprasidone:a novel anti psychotic agent with aunique human receptor binding profile[J].Eur J Pharmacol,2001,425(3):197.